Biotech Co. Faces Mounting ELEVIDYS Efficacy Risk as Roche Phase 3 Study Threatens US Franchise
Research Report

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for H.C. Wainwright & Co., Sarepta Therapeutics Inc., April 16, 2026

This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet. H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility. RETURN ASSESSMENT Market Outperform (Buy): The common stock of the company is expected to outperform a passive index comprised of all the common stock of companies within the same sector. Market Perform (Neutral): The common stock of the company is expected to mimic the performance of a passive index comprised of all the common stock of companies within the same sector. Market Underperform (Sell): The common stock of the company is expected to underperform a passive index comprised of all the common stock of companies within the same sector. Rating and Price Target History for: Sarepta Therapeutics, Inc. (SRPT-US) as of 04-15-2026 200 150 100 50 0 Q1 Q2 Q3 2024 Q1 Q2 Q3 2025 Q1 Q2 Q3 2026 Q1 Q2 D:UR:NA 10/08/20 I:SELL:$80.00 11/25/24 SELL:$75.00 12/02/24 NEUTRAL:$75.00 04/02/25 NEUTRAL:$40.00 05/07/25 SELL:$10.00 06/16/25 SELL:$0.00 07/21/25 SELL:$5.00 07/29/25 Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months. Distribution of Ratings Table as of April 15, 2026 IB Service/Past 12 Months Ratings Count Percent Count Percent Buy 556 82.99% 162 29.14% Neutral 62 9.25% 10 16.13% Sell 2 0.30% 0 0.00% Under Review 50 7.46% 16 32.00% H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer. I, Mitchell S. Kapoor and Raghuram Selvaraju, Ph.D. , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies. None of the research analysts or the research analyst’s household has a financial interest in the securities of Sarepta Therapeutics, Inc. (including, without limitation, any option, right, warrant, future, long or short position). As of March 31, 2026 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Sarepta Therapeutics, Inc.. Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report. H.C. WAINWRIGHT & CO. EQUITY RESEARCH 4 This report is intended for kdelbuono@streetwisereports.com. Unauthorized distribution prohibited. Sarepta Therapeutics, Inc. April 16, 2026 The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The Firm or its affiliates did not receive compensation from Sarepta Therapeutics, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report. The Firm does not make a market in Sarepta Therapeutics, Inc. as of the date of this research report. The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report. H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

On April 16, 2026, Mitchell S. Kapoor and Raghuram Selvaraju, Ph.D. of H.C. Wainwright & Co. reiterated a Sell rating and US$5.00 price target on Sarepta Therapeutics Inc. (SRPT:NASDAQ), implying approximately 77% downside from the April 15, 2026 closing price of US$21.73, following Roche's (RO.SW; not rated) announcement of a new placebo-controlled Phase 3 study of ELEVIDYS that the analysts believe creates meaningful downside risk for Sarepta's core U.S. franchise.

Roche Study Reopens Efficacy Debate

The analysts argue that while Roche's new randomized study is ostensibly aimed at reopening the European market for ELEVIDYS, it creates a fresh efficacy risk for Sarepta's most important revenue driver — U.S. ambulatory ELEVIDYS sales.

The EMBARK study previously missed its primary endpoint, the North Star Ambulatory Assessment (NSAA), and the European Committee for Medicinal Products for Human Use (CHMP) subsequently rejected the European regulatory package, concluding that the marginal NSAA benefit observed may have been due to chance and that truncated dystrophin could not be linked to improved movement abilities.

An FDA reviewer similarly noted that because the NSAA result at Week 52 was not statistically significant, Study 301 Part 1 failed to verify benefit, and that secondary endpoints were therefore subject to inflated Type 1 error. With Roche now conducting another placebo-controlled test of the same endpoint, the analysts believe the setup is unfavorable for a clean reversal, given the prior randomized study's failure on NSAA.

External Control Narrative Under Pressure

The analysts highlight that after the one-year placebo crossover ended the internal randomized control, Sarepta has increasingly relied on a propensity-weighted external control to support its long-term efficacy story. The firm contends this external control fails a critical validity check, noting it does not behave like EMBARK's own placebo arm at Year 1.

Should Roche's new study again fail to demonstrate a clean NSAA benefit, the analysts believe Sarepta would have significantly less room to argue that non-randomized comparisons can rescue a therapy that has repeatedly struggled to deliver statistically significant placebo-controlled proof on its core functional endpoint.

Commercial Strategy and Revenue Outlook

Sarepta's central commercial effort in 2026 is focused on rebuilding U.S. ambulatory demand, relying more heavily on long-term EMBARK follow-up data and external control comparisons. The analysts project total revenue will decline to US$1.75 billion in 2026 from US$2.20 billion in 2025, with ELEVIDYS product revenue expected to fall sharply to US$355.2 million from US$898.7 million in 2025.

Non-ELEVIDYS product revenue is expected to remain relatively stable at approximately US$945.0 million. The analysts project diluted EPS of US$4.15 for full-year 2026, compared to a loss of US$7.13 per diluted share in 2025.

Valuation and Risks

The analysts' US$5.00 price target is derived from a discounted cash flow analysis employing a 12% discount rate and a 2% terminal rate of decline, with projections running through 2045. After accounting for estimated end-2026 cash of approximately US$1.5 billion and debt of approximately US$800 million, the firm arrives at an equity valuation of US$618 million.

As of April 15, 2026, Sarepta's market capitalization stood at approximately US$2.28 billion, with cash of US$940.7 million and total debt of US$829.0 million on its balance sheet. The analysts assign 100% probability of approval to ELEVIDYS, Amondys 45, Exondys 51, and Vyondys 53.

Key upside risks cited include the possibility that the FDA reverses course on ELEVIDYS approval status in non-ambulatory patients, that Sarepta generates data supporting a path forward for ELEVIDYS in patients not susceptible to acute liver injury or liver failure, and additional favorable clinical data from development-stage assets.